A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer.

ABSTRACT:

Background

Whether the combination of gefitinib and chemotherapy is beneficial for advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to summarize the currently available evidence and compare the efficacy and safety of gefitinib combined with chemotherapy versus chemotherapy alone for treating advanced NSCLC.

Methods

Literature on comparing the effects of gefitinib combined with chemotherapy and chemotherapy alone in treating NSCLC was retrieved from the PubMed, EMBASE and Cochrane Database. The primary outcome measures included progression-free survival (PFS) and overall survival (OS). Revman 5.3 was used for data processing.

Results

Seven randomized controlled trials were included, involving a total of 1418 patients. There appeared a

SUBMITTER: Zhao Q 

PROVIDER: S-EPMC7402902 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature